Lifecore Scores Fourth Site Transfer in Five Months and Expands Ophthalmic Manufacturing
Lifecore Biomedical signed two CDMO agreements with an existing US biopharmaceutical customer, including a commercial site transfer for a marketed product and an expansion to a second ophthalmic delivery system. This fourth site transfer win in five months is projected to contribute to 2028 commercial revenue.
1. Agreement Details
Lifecore signed two CDMO service agreements with an existing US biopharmaceutical customer, including a commercial site transfer under which it will conduct PPQ batches and initiate commercial manufacture of a marketed product, and an expansion to produce an ophthalmic therapy in a second delivery system previously made in Europe.
2. Strategic Impact and Revenue Outlook
This marks Lifecore’s fourth commercial site transfer win in five months under its new strategy focused on late-stage programs, with both projects anticipated to contribute meaningful commercial revenue beginning in 2028 and further solidify its reputation in the injectable CDMO market.